UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 87,408 Shares of Oruka Therapeutics, Inc. $ORKA

Posted by Brian Himes on Sep 7th, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) by 517.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,310 shares of the company’s stock after buying an additional 87,408 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Oruka Therapeutics were worth $9,927,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ORKA. BlackRock Inc. purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $474,916,000. Viking Global Investors LP purchased a new position in Oruka Therapeutics during the third quarter valued at approximately $51,280,000. Deep Track Capital LP lifted its holdings in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after purchasing an additional 676,865 shares during the period. Finally, RTW Investments LP boosted its position in shares of Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after purchasing an additional 112,499 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ORKA has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Finally, Mizuho set a $120.00 target price on Oruka Therapeutics in a research report on Thursday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Check Out Our Latest Stock Report on Oruka Therapeutics

Oruka Therapeutics Stock Performance

ORKA opened at $92.51 on Monday. The stock has a market capitalization of $6.13 billion, a price-to-earnings ratio of -45.57 and a beta of -0.34. The company has a fifty day moving average of $95.24 and a 200 day moving average of $69.84. Oruka Therapeutics, Inc. has a fifty-two week low of $14.66 and a fifty-two week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00. Following the completion of the transaction, the insider owned 32,718 shares in the company, valued at $3,659,181.12. This trade represents a 17.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the sale, the director directly owned 38,743 shares in the company, valued at approximately $2,716,271.73. The trade was a 24.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 158,116 shares of company stock valued at $13,523,783 over the last three months. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Profile

(Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.